Treatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications

October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 147 | Copyright © October 2013


Stephanie Bayers BSBA,a Daniel L. Kapp MD FACS,b
Kenneth R. Beer MD FAAD,b and Benjamin Slavinc

aUniversity of Miami Miller School of Medicine, Miami, FL
bPalm Beach Plastic Surgery Center, West Palm Beach, FL
cUniversity of Miami, Miami, FL

not be breached. Metastatic BCC and BCCs that cannot be resected are rare. Whereas some of these non-resectable patients may be treated with radiation, many are not candidates for this modality due to proximity to vital structures. For these patients, vismodegib offers a valuable alternative for treatment.

DISCLOSURES

Kenneth Beer MD FAAD receives fees from Genentech for speaking and research. Stephanie Bayers BSBA, Daniel Kapp MD FACS, and Benjamin Slavin have no conflicts of interest to disclose.

REFERENCES

  1. Undén AB, Zaphiropoulos PG, Bruce K, Toftgård R, Ståhle-Bäckdahl M. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res. 1997;57(12):2336-2340.
  2. Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the Hedgehog receptor. Nature. 1996;384(6605):176-179.
  3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
  4. Halen ML, Ratner D, Patel A. Basal Cell Carcinoma. In: Alam M, ed. Evidence- Based Procedural Dermatology. New York: Springer Science + Business Media; 2012:38-39.
  5. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135(10):1177-1183.
  6. National Comprehensive Cancer Network®. NCCN Guidelines®: Basal Cell and Squamous Cell Skin Cancers. 2012. http://www.nccn.org/professionals/ physician_gls/pdf/nmsc.pdf. Accessed August 26 2013.
  7. Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg. 2011;30(suppl 4):s10-s13.
  8. Patel SS, Cliff SH, Ward Booth P. Incomplete removal of basal cell carcinoma: what is the value of further surgery? Oral Maxillofac Surg. 2013;17(2):115-118.
  9. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
  10. Geeraert P, Williams JS, Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. J Drugs Dermatol. 2013;12(5):519-523.
  11. Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Rev Drug Discov. 2012;11(6):437-438.
  12. Rudin CM. Vismodegib. Clin Cancer Res. 2012;18(12):3218-3222.
  13. Genentech Inc. Erivedge™ Prescribing Information. 2012. http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Accessed August 26 2013.
  14. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324-1325.
  15. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 2010;107(30):13432-13437.
  16. Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007;104(20):8455-8460.

AUTHOR CORRESPONDENCE

Kenneth Beer MD FAADkenbeer@aol.com